Just to add some caution. All these these new therapeutics - whether it's FX-322, REGAIN, CGF166, Hough's siRNA etc. - operate under the assumption that human supporting cells can induce hair cell growth. Until one of these companies/institutes releases Phase 2 results, we don't know if that's the case. Yes, there's promising in vitro and in vivo work, but as someone very wise once said: if mouse results were fully indicative of human results, humanity would be disease free by now. Plenty of drugs that showed promising results in in vivo work, eventually failed in human trials.
The other thing is that even if these theories hold up, there will still be a patient population that won't be helped, either because their hearing loss is too great (too few supporting cells), or the cause of their hearing loss is not hair cell related (neuropathy, Vestibular Schwannoma, brain damage etc.).
Another obstacle in treating hearing loss is the lack of diagnostic tools. There is no imaging technology or way to test perilymph of the inner ear to see what's going on in a patients inner ear. All we have are hearing tests, which are far from perfect. That makes screening patients for therapies a lot harder.
And then there's of course the problem of inner ear drug delivery, which I won't nag about again.